Alnylam Pharmaceuticals, Inc.

ALNY Healthcare Biotechnology

Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024. In the quarter to June 2026, revenue grew 66.9%, EPS grew 341.2%, free cash flow grew 152.8% and total debt fell 1.51%, each against the same quarter a year earlier. Member of the Nasdaq 100; revenue growth for five consecutive years.

231.83 2.20 −0.94%
Market cap
$31.3B
P/E
39.5×
Fwd P/E
39.6×
Dividend yield
—
F-score
6/9
Altman Z
7.30
Beneish M
−1.95
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

6 6 7 7
ROE
57.72% 73.28% 90.36% 96.55%
ROA
1.70% 6.82% 11.52% 15.30%
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
2.65% 10.13% 15.88% 21.16%
Average Days of Receivables
109.70 76.42 75.26 69.35
Free Cash Flow per Share
1.68 3.55 4.84 6.14
Free Cash Flow
221.36 465.38 643.34 819.87
Capital Expenditures
(44.50) (58.70) (71.56) (91.95)
Other line items
Cash ROIC
5.54% 9.89% 12.63% 14.45%
Accounts Receivable Turnover
4.87 6.28 6.59 6.49
Accounts Payable Turnover
5.49 6.68 7.34 9.29
Inventory Turnover
6.83 8.46 10.99 11.58
Average Days of Payables
83.02 61.94 56.23 40.34
Days of Inventory on Hand
53.22 44.28 37.31 36.26
Tax Rate
56.60 (0.03) (0.02) 0.01
Research and Development Expense of Revenue
38.87% 35.54% 33.11% 31.41%
Selling, General and Administrative Expense of Revenue
36.78% 32.60% 30.17% 27.43%
Share Based Compensation of Revenue
11.47% 9.38% 8.44% 7.01%
Interest Coverage
1.30 1.99 2.85 3.52
Operating CF/Net income
3.46 1.67 1.33 1.18
Depreciation/Fixed assets
0.11 0.11 0.11 0.10
Capex/Depreciation
(0.79) (1.05) (1.31) (1.68)
Revenue per Share
24.42 28.35 32.26 35.96
Operating CF per Share
2.02 4.00 5.38 6.82
Capex per Share
(0.34) (0.45) (0.54) (0.69)
Capex to Sales
0.01 0.02 0.02 0.02

Fold the line items

Columns are period end dates